Abiopharma

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues

New Form 8-K - Passage BIO, Inc. Filed: 2025-08-12 AccNo: 0001558370-25-011143 Size: 5 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - VERU INC. Filed: 2025-08-12 AccNo: 0001193125-25-178463 Size: 258 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - GLAUKOS Corp Filed: 2025-08-12 AccNo: 0001558370-25-011142 Size: 5 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Bruker - Bruker Announces Quarterly Dividend

New Form 10-Q - Milestone Pharmaceuticals Inc. Filed: 2025-08-12 AccNo: 0001558370-25-011141 Size: 7 MB

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Xtant Medical Reports Second Quarter 2025 Financial Results

Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates

New Form 8-K - CARDINAL HEALTH INC Filed: 2025-08-12 AccNo: 0000721371-25-000075 Size: 915 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Cardinal Health Reports Fourth Quarter and Fiscal Year 2025 Results and Raises Fiscal Year 2026 Guidance

New Form 10-Q - Neuraxis, INC Filed: 2025-08-12 AccNo: 0001641172-25-023100 Size: 7 MB